Ray Therapeutics Appoints Scott Braunstein, M.D., as Chairman of the Board of Directors [Yahoo! Finance]
Pacira BioSciences, Inc. (PCRX)
Last pacira biosciences, inc. earnings: 2/20 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.pacira.com
Company Research
Source: Yahoo! Finance
BERKELEY, Calif., January 08, 2026 BUSINESS WIRE Ray Therapeutics , a clinical-stage biotechnology company developing optogenetic gene therapies for vision restoration, today announced the appointment of Scott Braunstein, M.D., as Chairman of the company's Board of Directors. The company's lead program, RTx-015, is currently being evaluated in a Phase 1 clinical trial to treat retinitis pigmentosa (RP). Ray Therapeutics is also poised to dose the first patient in a Phase 1 clinical trial of RTx-021 for Stargardt disease. "We are excited and privileged to welcome Scott as Chairman of the Board," said Paul Bresge, CEO & Co-Founder, Ray Therapeutics. "Scott's unique background across clinical medicine, investment management, and executive leadership in biopharma will be instrumental as we advance RTx-015 and RTx-021 through the clinic. Scott's proven track record of guiding companies through strategic growth and value creation will help us progress our mission of restoring vision for
Show less
Read more
Impact Snapshot
Event Time:
PCRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PCRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PCRX alerts
High impacting Pacira BioSciences, Inc. news events
Weekly update
A roundup of the hottest topics
PCRX
News
- Do Options Traders Know Something About Pacira BioSciences Stock We Don't? [Yahoo! Finance]Yahoo! Finance
- Pacira Announces Agreement with LG Chem to Make EXPAREL® Available in Select Asian-Pacific MarketsGlobeNewswire
- How Investors May Respond To Pacira BioSciences (PCRX) Activist Pressure Amid Buybacks And Rising EXPAREL Revenue [Yahoo! Finance]Yahoo! Finance
- Pacira BioSciences (NASDAQ:PCRX) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $30.00 price target on the stock.MarketBeat
- Pacira BioSciences (NASDAQ:PCRX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock.MarketBeat
PCRX
Earnings
- 11/6/25 - Beat
PCRX
Sec Filings
- 1/9/26 - Form DFAN14A
- 1/8/26 - Form 8-K
- 1/6/26 - Form 4
- PCRX's page on the SEC website